Current Report Filing (8-k)

Date : 09/09/2019 @ 11:31AM
Source : Edgar (US Regulatory)
Stock : Aclaris Therapeutics Inc (ACRS)
Quote : 1.35  -0.03 (-2.17%) @ 12:59AM
After Hours
Last Trade
Last $ 1.35 ◊ 0.00 (0.00%)

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 3, 2019

 


 

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-37581

 

46-0571712

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

640 Lee Road, Suite 200

Wayne, PA 19087

(Address of principal executive offices, including zip code)

 

(484) 324-7933

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:

 

Trading
Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 


 

Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)                                 Resignation of Chief Scientific Officer

 

On September 3, 2019, Stuart D. Shanler, M.D. notified Aclaris Therapeutics, Inc. (the “Company”), that he will resign as Chief Scientific Officer of the Company.  Dr. Shanler is a co-founder of the Company.  Pursuant to his employment agreement, the resignation will take effect on October 3, 2019, unless the Company and Dr. Shanler agree to an earlier date prior to October 3, 2019.

 

(e)                                  Modified Compensation of Chief Executive Officer

 

On September 3, 2019, the Company’s board of directors approved a reduction of the annual base salary of Neal Walker, the Company’s Chief Executive Officer, from $566,500 per year to $300,000 per year, effective October 1, 2019.  In connection with such reduction, the Company’s board of directors also resolved to grant an equity award to Dr. Walker, with the terms of such equity award to be subsequently determined by the Company’s compensation committee.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ACLARIS THERAPEUTICS, INC.

 

 

 

 

By:

/s/ Frank Ruffo

Date: September 9, 2019

 

Frank Ruffo

 

 

Chief Financial Officer

 

3


Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Aclaris Therapeutics Charts.

Aclaris Therapeutics (NASDAQ:ACRS)
Intraday Stock Chart

Today : Sunday 16 February 2020

Click Here for more Aclaris Therapeutics Charts.

Latest ACRS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.